Regulation of Fat-stimulated Neurotensin Secretion in Healthy Subjects
Context: Cholecystokinin (CCK) and neurotensin are stimulated during meal intake by the presence of fat in the small intestine. The sequence of events suggests that fat hydrolysis is crucial for triggering the release.
Objectives: The aim of this study was therefore to investigate whether CCK mediated the effect of intraduodenal (ID) fat on neurotensin secretion via CCK-1 receptors.
|Study Design:||Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Basic Science
|Official Title:||Mechanistic Study (Physiology)|
- Neurotensin plasma concentrations [ Time Frame: Change in plasma cocnentrations over 2-3 hours ]
|Study Start Date:||January 2006|
|Study Completion Date:||March 2007|
|Primary Completion Date:||March 2007 (Final data collection date for primary outcome measure)|
A, 3; B, 3; C, 3
A, 3: Fat with and without orlistat or placebo. B, 3: LCF vs MCF vs placebo. C, 3: LCF with and without DEXLOX or placebo.
Dietary Supplement: Fat perfusion to the small intestine
Setting: Single center study; 34 male volunteers were studied in consecutive, randomized, double blind, crossover studies.
Subjects and Methods: CCK and neurotensin release were quantified in: 1) 12 subjects receiving an ID fat infusion with or without 60 mg orlistat, an irreversible inhibitor of gastrointestinal lipases, in comparison to vehicle. 2) 12 subjects receiving ID long chain fatty acids (LCF), ID medium chain fatty acids (MCF) or ID vehicle. 3) 10 subjects receiving ID LCF with and without the CCK-1 receptor antagonist dexloxiglumide (DEXLOX) or ID vehicle plus IV saline (placebo). Hormone concentrations were measured by specific RIA systems.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00541762
|Clinical Research Center, University Hospital|
|Basel, Switzerland, CH-4031|
|Principal Investigator:||Juergen Drewe, MD||University Hospital, 4031 Basel, Switzerland|
|Principal Investigator:||Christoph Beglinger, MD||Department of Research and Clinical Pharmacology, University Hospital, Basel Switzerland|